Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab with or without topical corticosteroids in moderate-to-severe atopic dermatitis (China Phase 3)
CTR20241024Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started May 2024; status: active.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241024.